Mentions of corporate governance increased in the pharmaceutical industry in Q1 2023
Notably, corporate governance was one of the most frequently referenced themes in Q1 2023, ranking highest in terms of mentions, ahead of artificial intelligence and environment, according to GlobalData.
Of the 50 leading companies in the pharmaceutical industry, GSK had the greatest increase in references for corporate governance in Q1 2023, compared with the previous quarter. GlobalData identified 524 corporate governance-related sentences in the company’s filings – 58% of all sentences – and an increase of 17300% in Q1 2023 compared with Q4 2022. Novartis’s mentions of corporate governance rose by 2500% to 267 and Pfizer’s by 1600% to 172 and Sanofi’s by 4800% to 149 and Novo Nordisk’s by 10200% to 103.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for corporate governance in Q1 2023 was 87.
To further understand GlobalData’s analysis on ESG (Environmental, Social and Governance) Survey on Pharmaceutical Manufacturing – Towards a Sustainable Supply Chain, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Company Filings Analytics uses machine learning to uncover key insights and track sentiment across millions of regulatory filings and other corporate disclosures for thousands of companies across the world’s largest industries.
Source link
#Mentions #corporate #governance #increased #pharmaceutical #industry
